FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
JPMorgan analyst Eric Joseph downgraded Pliant Therapeutics (NASDAQ: PLRX) from Overweight to Neutral.
The analyst comments "We are downgrading PLRX shares from Overweight to Neutral on the back of the voluntary pause of the BEACON-IPF (bexotegrast in IPF) trial announced Friday... More
H.C. Wainwright analyst Ed Arce downgraded Pliant Therapeutics (NASDAQ: PLRX) from Buy to Neutral.
The analyst comments "Our Take. This could turn out to be nothing, or it could spell the end for bexotegrast, if its a serious toxicity event(s) deemed likely due to study drug. Immediately following Friday's press... More
Pliant Therapeutics Inc. (NASDAQ: PLRX) 30-day option implied volatility is at 105; compared to its 52-week range of 56 to 118. Call put ratio 7.1 calls to 1 put with a focus on February 10 calls into pauses enrollment, dosing in BEACON-IPF Phase 2b trial.
... MoreRBC Capital analyst Brian Abrahams downgraded Pliant Therapeutics (NASDAQ: PLRX) from Outperform to Sector Perform with a price target of $4.00 (from $45.00).
For an analyst ratings summary and ratings history on Pliant Therapeutics click here. For more ratings news on Pliant Therapeutics click here.
Shares of Pliant Therapeutics closed at $7.79 yesterday.
... MoreWells Fargo analyst Tiago Fauth downgraded Pliant Therapeutics (NASDAQ: PLRX) from Overweight to Equal Weight with a price target of $4.00 (from $41.00).
For an analyst ratings summary and ratings history on Pliant Therapeutics click here. For more ratings news on Pliant Therapeutics click here.
Shares of Pliant Therapeutics closed at $7.79 yesterday.
... MoreCiti analyst David Lebowitz downgraded Pliant Therapeutics (NASDAQ: PLRX) from Buy to Neutral with a price target of $4.00 (from $40.00).
The analyst comments: "After the close on Friday, Pliant announced it has voluntarily paused enrollment and dosing for the BEACON-IPF Ph2b/3 study which examines... More
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendations by the trials independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). Patients currently enrolled in BEACON-IPF will remain in the trial.
Enrollment and dosing have been paused while data is reviewed to understand the DSMBs rationale for their recommendation. Blinding of the study will be maintained to preserve trial integrity. The Company has informed... More
